Novo Nordisk A/S
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, March 29, 2023. George Frey | Reuters Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread […]
Read More
Pounds-loss drug Wegovy could get expanded Food and drug administration approval inside of six months, Novo Nordisk states
Even now daily life of Wegovy an injectable prescription fat decline medication that has aided people with being overweight. It should be made use of with a bodyweight loss system and physical activity. Michael Siluk | UCG | Getty Photographs Novo Nordisk said Thursday that its blockbuster bodyweight-reduction drug Wegovy could acquire expanded acceptance from […]
Read More
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions. Here’s […]
Read More
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
CFOTO | Future Publishing | Getty Images Pfizer on Tuesday reported a narrower than expected loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and Covid vaccine. Pfizer said that it recorded a $5.6 billion charge for inventory write-offs in the third quarter due […]
Read More
Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don’t expect this duopoly to end soon, analysts say. But other companies — both big and small — are hoping to grab a piece of this lucrative market. In a research note, Piper Sandler analyst Yasmeen Rahimi said the firm is tracking more […]
Read More
As Ozempic and Wegovy take off, this tech startup just lifted $20 million to deal with body weight loss with facts
Weight loss has usually been major organization, but it can be exploded of late thanks to surging demand for Ozempic, Wegovy and other new diabetes and being overweight prescription drugs. In the initially 50 percent of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively. Which is just after quarterly prescriptions for […]
Read More
CNBC Day by day Open up: Oil deals ahead of Large Tech earnings
Omar Marques | Lightrocket | Getty Photographs This report is from today’s CNBC Day-to-day Open up, our new, international markets publication. CNBC Day-to-day Open up delivers buyers up to speed on almost everything they need to know, no subject where by they are. Like what you see? You can subscribe right here. What you need to […]
Read More
AI, excess weight decline medicine and additional: Portfolio manager names stocks to perform ‘new secular progress themes’
Marketplaces may well be dealing with an “unconventional total” of uncertainty, but there continue to are really fantastic chances ideal, in accordance to a single portfolio supervisor, who tells CNBC Professional about three new expansion spots and the shares he likes. There are numerous “cross currents” in the industry correct now, claimed Sanjay Ayer of […]
Read More
Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That viewpoint seems […]
Read More
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition. In […]
Read More